NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue
NeoGenomics (NASDAQ: NEO) reported Q2 CY2026 revenue of $201.7 million, up 11.2% year over year, exceeding Wall Street estimates by 2.2%. Non-GAAP EPS was $0.05, above consensus by $0.02. The company guided full-year revenue to about $804 million and expects EPS to rise from $0.15 to $0.29.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results beat revenue and adjusted EPS expectations, and the company’s full-year revenue guidance is described as close to estimates, which can re-rate near-term expectations. However, the article emphasizes negative adjusted operating margin, keeping execution risk elevated.
Market read
A concrete earnings/guidance beat with a same-day stock move (up 5% to $14.08) makes this actionable for traders managing post-earnings positioning.
What to watch
Investors may focus less on revenue growth and more on the path to durable profitability, since the article flags negative adjusted operating margin over the last five years and only modest improvement recently.
Background
NeoGenomics operates CAP-accredited and CLIA-certified oncology diagnostics labs in the US and UK, providing genetic and molecular testing plus pathology consultation.
Ticker impact
NeoGenomics reported Q2 CY2026 revenue of $201.7M, up 11.2% YoY, and adjusted EPS of $0.05, beating consensus.
Likely near-term upside bias versus pre-report expectations, with follow-through dependent on margin trajectory and whether guidance holds.
The article provides concrete Q2 results (revenue, EPS) and full-year revenue guidance, but also highlights negative adjusted operating margin (negative 0.8% in Q2) and longer-term unprofitability, which can cap the rally.
Market effects
Positive read-through for oncology diagnostics demand and lab utilization, but margin weakness underscores sector profitability risk.
Primarily US-focused lab network; UK operations add diversification but no specific regional catalyst is cited.
Limited global impact beyond healthcare diagnostics sentiment; no international regulatory or competitive event mentioned.
Counterpoint
The headline beat may not translate into sustained upside because adjusted operating margin remains negative and the business has struggled with an expensive cost structure.
Key entities
- companyNeoGenomics
Oncology diagnostics provider reporting Q2 CY2026 revenue and adjusted EPS, plus full-year revenue guidance.
- executiveTony Zook
CEO quoted on the quarter’s operating and financial performance.
